Meeting
2023 ASCO Annual Meeting
First report of ELUCIDATOR study: A prospective observational multicenter study on resistance mechanisms in patients with early disease progression during osimertinib.
Authors
Yasuyuki Mizumori
National Hospital Organization Himeji Medical Center, Himeji, Japan
Yasuyuki Mizumori , Akihiro Tamiya , Mitsuo Osuga , Shun-ichi Isa , Yoshihiko Taniguchi , Keiichi Nakamura , Daijiro Harada , Tsutomu Shinohara , Hidetoshi Yanai , Katsumi Nakatomi , Masahide Oki , Masahide Mori , Tomohito Kuwako , Koji Yamazaki , Atsuhisa Tamura , Masahiko Ando , Yasuhiro Koh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Clinical Trial Registration Number
jRCTs031180051
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3032)
DOI
10.1200/JCO.2023.41.16_suppl.3032
Abstract #
3032
Poster Bd #
230
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Association of alterations in multiple tumor suppressor genes with poor outcomes in patients with EGFR-mutant lung cancer.
First Author: Paul Stockhammer
Poster
2021 ASCO Annual Meeting
Targeted ctDNA sequencing analysis reveals concurrent genomic alterations and its impact on TKI and immune checkpoint inhibitor therapy in advanced NSCLC from Asian population.
First Author: Wei Wu
Poster
2023 ASCO Annual Meeting
Tissue and plasma-based mechanisms of resistance to first-line osimertinib in EGFR-mutant NSCLC: A multi-institutional cohort.
First Author: Zofia Piotrowska
Poster
2023 ASCO Annual Meeting
Elucidating the genomic and transcriptomic landscape of L858R vs ex19del EGFR-mutated NSCLC.
First Author: Stephanie Pei Li Saw